JP Patent

JP6337170B2 — ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト

Assigned to ベーリンガーインゲルハイムフェトメディカゲゼルシャフトミットベシュレンクテルハフツング · Expires 2018-06-06 · 8y expired

What this patent protects

Patent listed against atrasentan-hydrochloride.

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

Patent Metadata

Patent number: JP6337170B2
Jurisdiction: JP
Classification: —
Expires: 2018-06-06
Drug substance claim: No
Drug product claim: No
Assignee: ベーリンガーインゲルハイムフェトメディカゲゼルシャフトミットベシュレンクテルハフツング
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.